Results 291 to 300 of about 269,407 (342)

Efficacy and safety of CT‐868, a novel, fully biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double‐blind, randomized placebo controlled phase 2 trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To assess the glycaemic efficacy and safety of CT‐868, a cAMP signal‐biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in participants with type 2 diabetes (T2D). Materials and Methods This 26‐week (W), phase 2, randomized, double‐blind placebo‐controlled trial enrolled adults with T2D ...
Manu V. Chakravarthy   +10 more
wiley   +1 more source

Hematoma

open access: yes, 2018
Daniel Bell   +2 more
openaire   +1 more source

Two Cases of Less Common Clinical Presentations of Allergic Contact Dermatitis to Acrylates in UV‐Cured Nail Polish

open access: yes
Contact Dermatitis, EarlyView.
Léopoldine Vernhet   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy